CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
The new Learning Center website launch today on Monday, March 30, 2020. While the link to the new Le...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
CTS will be revising some forms in use by clients on October 26, 2020. We do try to limit form chang...
The FDA Guidance ZIKV video for the webinar held on 08/15/18 has been posted in the Wh...
The new online Learning Center with new content can still be found under the “Training” folder on ...